Needham analyst Chad Messer maintained a Buy rating on Akebia Therapeutics (NASDAQ:AKBA) on Thursday, setting a price target of $10, which is approximately 0.00% below the present share price of $10.
Messer expects Akebia Therapeutics to post earnings per share (EPS) of -$0.47 for the third quarter of 2020.
The current consensus among 5 TipRanks analysts is for a Strong Buy rating of shares in Akebia Therapeutics, with an average price target of $12.8.
The analysts price targets range from a high of $17 to a low of $8.
In its latest earnings report, released on 03/31/2020, the company reported a quarterly revenue of $88.48 million and a net profit of -$59.13 million. The company's market cap is $1.43 billion.
According to TipRanks.com, Needham analyst Chad Messer is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 9.3% and a 46.67% success rate.
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney disease. The firm also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.